1088 Bardoxolone improves investigative SSc fibrosis

Systemic sclerosis (SSc) is a heterogenous immune-mediated fibrotic disease. Disability of daily life in SSc patients largely depending on skin fibrosis starting distal site limb. However, there limited randomized control trial (RCT)-proven therapies for SSc. The effect anti-fibrotic drug, including transforming growth factor (TGF)-beta ab, peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, and tyrosine kinase inhibitor was various between patients. In the clinical situation, it crucial to know best drug protocol specific patient facing rather than result RCT. We, therefore, explanted fibroblasts from SSc, which were cultured with multiple drugs, such as or PPAR-gamma/NF-E2-related factor2 (Nrf2) agonist: bardoxolone, exclusively, since fundamentally collagen deposition released fibroblasts. responses different patients’ fibroblasts: some preferentially blocked by PPAR-gamma/Nrf2 agonists inhibitor; however, other effectively vitro. Thus, possible test candidate agents individual before long term decision making. Recently, selection based gene signature has been named “precision medicine”, providing efficient direct selection. current approach could de-escalate recent therapeutic strategy new precision medicine